Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)

NCT01920932 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT01920932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01920932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 12, 2013
Completion date
May 31, 2028
Enrollment
77 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii childhood hodgkin lymphoma, stage iii childhood hodgkin lymphoma, stage iv childhood hodgkin lymphoma